U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H37F2N7O4.C4H6O6
Molecular Weight 783.775
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GOLVATINIB TARTRATE

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.CN1CCN(CC1)C2CCN(CC2)C(=O)NC3=NC=CC(OC4=CC=C(NC(=O)C5(CC5)C(=O)NC6=CC=C(F)C=C6)C(F)=C4)=C3

InChI

InChIKey=JYFKDBFPRXMUAM-LREBCSMRSA-N
InChI=1S/C33H37F2N7O4.C4H6O6/c1-40-16-18-41(19-17-40)24-9-14-42(15-10-24)32(45)39-29-21-26(8-13-36-29)46-25-6-7-28(27(35)20-25)38-31(44)33(11-12-33)30(43)37-23-4-2-22(34)3-5-23;5-1(3(7)8)2(6)4(9)10/h2-8,13,20-21,24H,9-12,14-19H2,1H3,(H,37,43)(H,38,44)(H,36,39,45);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1

HIDE SMILES / InChI

Molecular Formula C33H37F2N7O4
Molecular Weight 633.6882
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=640626 https://www.ncbi.nlm.nih.gov/pubmed/19832844

Golvatinib is a highly potent, small-molecule, ATP-competitive inhibitor of c-Met and multiple members of the Eph receptor family plus c-Kit and Ron. Eisai was developing an oral formulation of golvatinib, which acts as both a c-Met inhibitor and a vascular endothelial growth factor receptor 2 antagonist with potential antineoplastic activity. Golvatinib binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of various tumor cell types and play important roles in tumor cell growth, migration and angiogenesis. Clinical trials involving several forms of cancer are currently underway.

Approval Year

AUC

AUC

ValueDoseCo-administeredAnalytePopulation
171000 ng × h/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GOLVATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
45 h
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
GOLVATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
450 mg 1 times / day multiple, oral
Highest studied dose
Dose: 450 mg, 1 times / day
Route: oral
Route: multiple
Dose: 450 mg, 1 times / day
Sources: Page: p.6287
unhealthy, ADULT
n = 2
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 2
Sources: Page: p.6287
DLT: Fatigue, Fatigue...
Disc. AE: Vomiting...
Dose limiting toxicities:
Fatigue (grade 2, 50%)
Fatigue (grade 3, 50%)
AEs leading to
discontinuation/dose reduction:
Vomiting (50%)
Sources: Page: p.6287
200 mg 2 times / day multiple, oral
MTD
Dose: 200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 200 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 3
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 3
Sources:
400 mg 1 times / day multiple, oral
MTD
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.6287
unhealthy, ADULT
n = 16
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 16
Sources: Page: p.6287
Disc. AE: Fatigue, Anorexia...
AEs leading to
discontinuation/dose reduction:
Fatigue (12.5%)
Anorexia (12.5%)
Sources: Page: p.6287
300 mg 2 times / day multiple, oral
Studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 2
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 2
Sources:
DLT: ALT increased...
Other AEs: Vomiting, Nausea...
Dose limiting toxicities:
ALT increased (grade 3, 50%)
Other AEs:
Vomiting (grade 2, 50%)
Nausea (grade 2, 50%)
Anorexia (grade 2, 50%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Vomiting 50%
Disc. AE
450 mg 1 times / day multiple, oral
Highest studied dose
Dose: 450 mg, 1 times / day
Route: oral
Route: multiple
Dose: 450 mg, 1 times / day
Sources: Page: p.6287
unhealthy, ADULT
n = 2
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 2
Sources: Page: p.6287
Fatigue grade 2, 50%
DLT, Disc. AE
450 mg 1 times / day multiple, oral
Highest studied dose
Dose: 450 mg, 1 times / day
Route: oral
Route: multiple
Dose: 450 mg, 1 times / day
Sources: Page: p.6287
unhealthy, ADULT
n = 2
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 2
Sources: Page: p.6287
Fatigue grade 3, 50%
DLT, Disc. AE
450 mg 1 times / day multiple, oral
Highest studied dose
Dose: 450 mg, 1 times / day
Route: oral
Route: multiple
Dose: 450 mg, 1 times / day
Sources: Page: p.6287
unhealthy, ADULT
n = 2
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 2
Sources: Page: p.6287
Anorexia 12.5%
Disc. AE
400 mg 1 times / day multiple, oral
MTD
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.6287
unhealthy, ADULT
n = 16
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 16
Sources: Page: p.6287
Fatigue 12.5%
Disc. AE
400 mg 1 times / day multiple, oral
MTD
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources: Page: p.6287
unhealthy, ADULT
n = 16
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 16
Sources: Page: p.6287
Anorexia grade 2, 50%
300 mg 2 times / day multiple, oral
Studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 2
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 2
Sources:
Nausea grade 2, 50%
300 mg 2 times / day multiple, oral
Studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 2
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 2
Sources:
Vomiting grade 2, 50%
300 mg 2 times / day multiple, oral
Studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 2
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 2
Sources:
ALT increased grade 3, 50%
DLT
300 mg 2 times / day multiple, oral
Studied dose
Dose: 300 mg, 2 times / day
Route: oral
Route: multiple
Dose: 300 mg, 2 times / day
Sources:
unhealthy, ADULT
n = 2
Health Status: unhealthy
Condition: cancer
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Population Size: 2
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Golvatinib at the MTD of 400 mg once daily was well tolerated with pharmacodynamic evidence of c-Met target modulation.
Route of Administration: Oral
Golvatinib strongly inhibits the growth of MKN45, EBC-1, Hs746T, and SNU-5 tumor cells with IC50 values of 37, 6.2, 23, and 24 nM, respectively
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:38:06 UTC 2023
Edited
by admin
on Sat Dec 16 01:38:06 UTC 2023
Record UNII
47S9L68C0N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GOLVATINIB TARTRATE
USAN   WHO-DD  
USAN  
Official Name English
GOLVATINIB TARTRATE [USAN]
Common Name English
Golvatinib tartrate [WHO-DD]
Common Name English
1,1-CYCLOPROPANEDICARBOXAMIDE, N-(2-FLUORO-4-((2-(((4-(4-METHYL-1-PIPERAZINYL)-1-PIPERIDINYL)CARBONYL)AMINO)-4-PYRIDINYL)OXY)PHENYL)-N'-(4-FLUOROPHENYL)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (1:1)
Common Name English
ER-396901-08
Code English
Code System Code Type Description
EPA CompTox
DTXSID80143505
Created by admin on Sat Dec 16 01:38:06 UTC 2023 , Edited by admin on Sat Dec 16 01:38:06 UTC 2023
PRIMARY
ChEMBL
CHEMBL3039525
Created by admin on Sat Dec 16 01:38:06 UTC 2023 , Edited by admin on Sat Dec 16 01:38:06 UTC 2023
PRIMARY
FDA UNII
47S9L68C0N
Created by admin on Sat Dec 16 01:38:06 UTC 2023 , Edited by admin on Sat Dec 16 01:38:06 UTC 2023
PRIMARY
DRUG BANK
DBSALT002115
Created by admin on Sat Dec 16 01:38:06 UTC 2023 , Edited by admin on Sat Dec 16 01:38:06 UTC 2023
PRIMARY
PUBCHEM
24771321
Created by admin on Sat Dec 16 01:38:06 UTC 2023 , Edited by admin on Sat Dec 16 01:38:06 UTC 2023
PRIMARY
NCI_THESAURUS
C166734
Created by admin on Sat Dec 16 01:38:06 UTC 2023 , Edited by admin on Sat Dec 16 01:38:06 UTC 2023
PRIMARY
SMS_ID
300000044598
Created by admin on Sat Dec 16 01:38:06 UTC 2023 , Edited by admin on Sat Dec 16 01:38:06 UTC 2023
PRIMARY
CAS
1007601-96-8
Created by admin on Sat Dec 16 01:38:06 UTC 2023 , Edited by admin on Sat Dec 16 01:38:06 UTC 2023
PRIMARY
USAN
YY-86
Created by admin on Sat Dec 16 01:38:06 UTC 2023 , Edited by admin on Sat Dec 16 01:38:06 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE